With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lyme Disease in the News
Development of Claros1 Analyzer for Lyme disease, which affects 300,000 new patients each year. This is being funded by a $3 million grant awarded …
To read more, click here:
https://www.google.com/url?rct=j&sa=t&url=http://seekingalpha.com/article/3104126-with-3-near-term-catalysts-and-heavy-insider-buying-this-biotech-should-be-in-your-portfolio-now%3Fsource%3Dgoogle_news&ct=ga&cd=CAIyGjYzNjRkY2VkODA2NzNmYjM6Y29tOmVuOlVT&usg=AFQjCNGfED6qBRli7b9Ap-RJFz9i21wHmA